ImmunoPrecise Antibodies Ltd (IPA)
1.225
-0.02
(-2.00%)
USD |
NASDAQ |
May 02, 10:27
ImmunoPrecise Antibodies Enterprise Value: 28.27M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 28.27M |
| April 30, 2024 | 29.05M |
| April 29, 2024 | 31.42M |
| April 26, 2024 | 30.11M |
| April 25, 2024 | 26.79M |
| April 24, 2024 | 27.48M |
| April 23, 2024 | 27.48M |
| April 22, 2024 | 28.27M |
| April 19, 2024 | 28.53M |
| April 18, 2024 | 28.00M |
| April 17, 2024 | 28.79M |
| April 16, 2024 | 29.32M |
| April 15, 2024 | 28.00M |
| April 12, 2024 | 31.16M |
| April 11, 2024 | 31.42M |
| April 10, 2024 | 31.95M |
| April 09, 2024 | 31.69M |
| April 08, 2024 | 32.74M |
| April 05, 2024 | 33.27M |
| April 04, 2024 | 33.53M |
| April 03, 2024 | 33.53M |
| April 02, 2024 | 34.05M |
| April 01, 2024 | 35.63M |
| March 28, 2024 | 35.37M |
| March 27, 2024 | 36.69M |
| Date | Value |
|---|---|
| March 26, 2024 | 35.37M |
| March 25, 2024 | 35.37M |
| March 22, 2024 | 36.69M |
| March 21, 2024 | 32.21M |
| March 20, 2024 | 32.48M |
| March 19, 2024 | 33.53M |
| March 18, 2024 | 32.21M |
| March 15, 2024 | 33.27M |
| March 14, 2024 | 37.21M |
| March 13, 2024 | 38.26M |
| March 12, 2024 | 38.53M |
| March 11, 2024 | 41.42M |
| March 08, 2024 | 43.79M |
| March 07, 2024 | 43.79M |
| March 06, 2024 | 36.95M |
| March 05, 2024 | 38.26M |
| March 04, 2024 | 41.95M |
| March 01, 2024 | 44.84M |
| February 29, 2024 | 43.92M |
| February 28, 2024 | 43.00M |
| February 27, 2024 | 44.32M |
| February 26, 2024 | 44.32M |
| February 23, 2024 | 45.37M |
| February 22, 2024 | 40.63M |
| February 21, 2024 | 40.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
19.41M
Minimum
Feb 20 2020
303.24M
Maximum
Dec 29 2020
82.06M
Average
75.01M
Median
Enterprise Value Benchmarks
| Acasti Pharma Inc | 1.675M |
| Aurinia Pharmaceuticals Inc | 393.21M |
| Edesa Biotech Inc | 9.854M |
| Lexaria Bioscience Corp | 39.61M |
| Xenon Pharmaceuticals Inc | 2.568B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.177M |
| Revenue (Quarterly) | 4.606M |
| Total Expenses (Quarterly) | 7.078M |
| EPS Diluted (Quarterly) | -0.0814 |
| Gross Profit Margin (Quarterly) | 51.39% |
| Profit Margin (Quarterly) | -47.26% |
| Earnings Yield | -33.86% |
| Normalized Earnings Yield | -33.73 |